ˌɛsbˈiːkˈæd ɪz ɪŋklˈuːdᵻd æz ɐ sˈɛkəndɚɹi tˈɑːɹɡɪt kəndˈɪʃən ɪn mˈoʊst nˈuːbɔːɹn skɹˈiːnɪŋ pɹˈoʊɡɹæmz, æz ðə kˈiː ˈænɐlˌaɪt ɪz ðə sˈeɪm ˌæzˌɪz jˈuːzd tʊ aɪdˈɛntᵻfˌaɪ ˌaɪsuːvɐlˈɛɹɪk ɐsaɪdˈiːmiə.
SBCADD is included as a secondary target condition in most newborn screening programs, as the key analyte is the same as is used to identify isovaleric acidemia.